View Older Stories View More Recent Stories
-
Cosmos Health (COSM) Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash
-
Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market
-
Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share
-
Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar
-
Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland
-
Cosmos Health (COSM) Signs Distribution Agreement with ProMed Trading
-
Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity
-
Cosmos Health (COSM) Updates on Contract Manufacturing Division
-
Cosmos Health (COSM) Regains Compliance with Nasdaq Minimum Bid Price Rule
-
Cosmos Health's (COSM) Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals
-
Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units
-
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule
-
Cosmos Health (COSM) Advances Commercialization of CCX0722 Weight Management Solution
-
Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market
-
Cosmos Health's (COSM) Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually
-
Cosmos Health's Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually
-
Cosmos Health (COSM) Expands Collaboration with Papaellinas in Cyprus; Sky Premium Life Sales Expected to More Than Double to 150,000 Units Over Next 12 Months
-
Cosmos Health Expands Collaboration with Papaellinas in Cyprus; Sky Premium Life Sales Expected to More Than Double to 150,000 Units Over Next 12 Months
-
Cosmos Health Signs Distribution Agreement with ZENDON s.r.o. in Slovakia, Hungary, Poland, and Czechia for Its Sky Premium Life Nutraceutical Products; Gains Access to More than 6,000 Stores of Leadi
-
Cosmos Health (COSM) Signs Exclusive Distribution Agreement with Pharmalink
-
Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units
-
Cosmos Health (COSM) to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent
-
Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent
-
Cosmos Health Completes Acquisition of Pelofarm's Pharmacy Distribution Network; Annual Revenue Poised to Grow by Over $5 Million
